Initial Vancomycin Taper for the Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial - PubMed
5 hours ago
- #clinical trial
- #Clostridioides difficile
- #vancomycin
- Study on vancomycin taper for preventing recurrent Clostridioides difficile infection (rCDI).
- Randomized clinical trial at 12 Canadian hospitals with 265 participants.
- Compared 4-week vancomycin pulse and taper vs. 2-week pulse regimen.
- Primary outcome: 14.8% recurrence in taper group vs. 17.7% in pulse group at day 56.
- Secondary outcome: 6.7% recurrence in taper group vs. 15.4% in pulse group at day 38.
- Posterior probability of superiority for taper regimen was 73.8% at day 56 and 99.0% at day 38.
- Adverse effects were rare in both groups.
- Trial stopped early due to recruitment feasibility.
- Vancomycin taper may be a safe and accessible option to delay or prevent early rCDI.